BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19238628)

  • 1. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
    André T; Reyes-Vidal JM; Fartoux L; Ross P; Leslie M; Rosmorduc O; Clemens MR; Louvet C; Perez N; Mehmud F; Scheithauer W
    Br J Cancer; 2008 Sep; 99(6):862-7. PubMed ID: 19238628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
    Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
    Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
    Manzione L; Romano R; Germano D
    Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
    André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
    Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.
    Hollebecque A; Bouché O; Romano O; Scaglia E; Cattan S; Zerbib P; Heurgue A; Lagarde S; Mariette C; Triboulet JP; Pruvot FR; Hebbar M
    Chemotherapy; 2010; 56(3):234-8. PubMed ID: 20551640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
    Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
    BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
    Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
    Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
    Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
    Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
    Williams KJ; Picus J; Trinkhaus K; Fournier CC; Suresh R; James JS; Tan BR
    HPB (Oxford); 2010 Aug; 12(6):418-26. PubMed ID: 20662793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.
    Harder J; Riecken B; Kummer O; Lohrmann C; Otto F; Usadel H; Geissler M; Opitz O; Henss H
    Br J Cancer; 2006 Oct; 95(7):848-52. PubMed ID: 16969352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.
    Bréchon M; Dior M; Dréanic J; Brieau B; Guillaumot MA; Brezault C; Mir O; Goldwasser F; Coriat R
    Invest New Drugs; 2018 Feb; 36(1):156-162. PubMed ID: 28762171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.